Microfluidic Synthesis of Hybrid Nanoparticles with Controlled Lipid Layers: Understanding Flexibility-Regulated Cell–Nanoparticle Interaction

Zhang, Lu; Feng, Qiang; Wang, Jiuling; Zhang, Shuai; Ding, Baoquan; Wei, Yujie; Dong, Mingdong; Ryu, Jiyoung; Yoon, Tae–Young; Shi, Xinghua; Sun, Jiashu; Jiang, Xingyu

doi:10.1021/acsnano.5b05792

Cited by 167 publications

(133 citation statements)

References 42 publications

(83 reference statements)

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…More importantly, their shell rigidity was controlled to regulate the cellular uptake. Sun et al prepared LPNs having structures of PLGA-lipid and PLGA-water-lipid (by altering the injection order of the PLGA and lipid-PEG organic solutions in the microfluidic chips) which had Young's modulus of 1.2 and 0.76 GPa, respectively (Sun et al, 2015). They found that the more rigid NPs had a much higher cellular uptake than the less rigid ones.…”

Section: Hybrid Nanoparticlesmentioning

confidence: 99%

“…Copyright (2010) American Chemical Society. (Sun et al, 2015) 28 † High throughput: ≥1 g/h; low throughput: < 1 g/h. Abbreviation: PLGA, poly(lactic-co-glycolic acid); DSPE-PEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol); DPPC, dipalmitoylsn-glycero-3-phosphocholine; NIPA, N-isopropylacrylamide; DCP, dihexadecyl phosphate; EPC, L-α-phosphatidylcholine (egg PC); n/a, not available.…”

Section: Hybrid Nanoparticlesmentioning

confidence: 99%

“…LPNs show promising prospect in the delivery of both hydrophilic and hydrophobic drugs such as doxorubicin (Wong et al, 2006;Zhang et al, 2015) and docetaxel (Liu et al, 2010) Fig. 8) , demonstrating the versatility of hybrid nanoparticles in encapsulating various types of cargoes.…”

Section: Hybrid Nanoparticlesmentioning

confidence: 99%

See 2 more Smart Citations

Multiphase microfluidic synthesis of micro- and nanostructures for pharmaceutical applications

Ran

Sun

Baby

et al. 2017

Chemical Engineering Science

View full text Add to dashboard Cite

Multiphase microfluidics has attracted significant interest in making micro-and nanostructures for various applications because of its capabilities in precisely controlling and manipulating a small volume of liquids. In this review, we introduce the recent advances in making micro-and nanostructures for pharmaceutical applications, including microparticles and microcapsules for controlled release, nanoparticles for drug delivery and microgels for 3D cell culture. With the development of more advanced microfluidic systems, the research focus in this field has shifted from making simple micro-and nanostructures to multifunctional systems to achieve more desirable functions. However, these multifunctions may lose their advantages that have been demonstrated in vitro once they are applied in vivo or later in human. The key challenge is a lack of fundamental understanding of the interactions between the micro-and nanomaterials and the biology systems. Consequently, the translation of these advanced materials lags far behind their extensive laboratory research.To better understand the micro-or nano-bio interactions, the development of new in vivomimicking models is imperative. Microfluidics has demonstrated its great potential in creating physiologically relevant models including 3D cell culture, tumor-on-a-chip and organs-on-a-chip. Therefore, efforts towards developing 3D cell culture and biomimetic chips including tumor-on-a-chip and organs-on-chips for faster and reliable evaluation of these micro-and nanosystems are also highlighted.

show abstract

Section: Hybrid Nanoparticlesmentioning

confidence: 99%

Section: Hybrid Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Multiphase microfluidic synthesis of micro- and nanostructures for pharmaceutical applications

Ran

Sun

Baby

et al. 2017

Chemical Engineering Science

View full text Add to dashboard Cite

show abstract

“…Indeed, the lipid system is undoubtedly one of the most popular nonviral vehicles for gene delivery. [11][12][13][14][15][16][17] The lipid bilayer can protect nucleic acids from degradation and enable efficient endosomal escape. 18,19 However, the present lipid systems, such as Lipofectamine 3000, are still not competent to deliver CRISPR/Cas9 because of their relatively low transfection efficiency.…”

Section: Introductionmentioning

confidence: 99%

Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy

Zhang

Wang²,

Feng³

et al. 2017

NPG Asia Mater

Self Cite

150

118

View full text Add to dashboard Cite

The emerging CRISPR/Cas9 system represents a promising platform for genome editing. However, its low transfection efficiency is a major problem hampering the application of the gene-editing potential of CRISPR/Cas9. Herein, by screening a pool of more than 56 kinds of agents, we constructed a novel polyethylene glycol phospholipid-modified cationic lipid nanoparticle (PLNP)-based delivery system that can condense and encapsulate a Cas9/single-guide RNA (sgRNA) plasmid (DNA) to form a core-shell structure (PLNP/DNA) that mediated up to 47.4% successful transfection of Cas9/sgPLK-1 plasmids in A375 cells in vitro. An intratumor injection of Cas9/sgPLK-1 plasmids into melanoma tumor-bearing mice resulted in significant downregulation of Pololike kinase 1 (PLK-1) protein and suppression of the tumor growth (467%) in vivo. This approach provides a versatile method that could be used for delivering the CRISPR/Cas9 system with high efficiency and safety both in vitro and in vivo.

show abstract

“…Microparticles have been extensively studied as delivery vehicles of proteins, peptides, and some small molecule drugs [1][2][3][4][5][6]. Compared with conventional forms of drug delivery via long-term frequent oral intake or injections to maintain a constant drug concentration, microparticle-based delivery systems can control both the level of the drugs and their lifetime in the body, and improve pharmacokinetics by sustained release of the drugs.…”

Section: Introductionmentioning

confidence: 99%

Composite core-shell microparticles from microfluidics for synergistic drug delivery

Yan

et al. 2017

Sci. China Mater.

View full text Add to dashboard Cite

Microparticles have a demonstrated value for drug delivery systems. The attempts to develop this technology focus on the generation of featured microparticles for improving the function of the systems. Here, we present a new type of microparticles with gelatin methacrylate (GelMa) cores and poly(L-lactide-co-glycolide) (PLGA) shells for synergistic and sustained drug delivery applications. The microparticles were fabricated by using GelMa aqueous solution and PLGA oil solution as the raw materials of the microfluidic double emulsion templates, in which hydrophilic and hydrophobic actives, such as doxorubicin hydrochloride (DOX, hydrophilic) and camptothecine (CPT, hydrophobic), could be loaded respectively. As the inner cores were polymerized in the microfluidics when the double emulsions were formed, the hydrophilic actives could be trapped in the cores with high efficiency, and the rupture or fusion of the cores could be avoided during the solidification of the microparticle shells with other actives. The size and component of the microparticles can be easily and precisely adjusted by manipulating the flow solutions during the microfluidic emulsification. Because of the solid structure of the resultant microparticles, the encapsulated actives were released from the delivery systems only with the degradation of the biopolymer layers, and thus the burst release of the actives was avoided. These features of the microparticles make them ideal for drug delivery applications.

show abstract

Microfluidic Synthesis of Hybrid Nanoparticles with Controlled Lipid Layers: Understanding Flexibility-Regulated Cell–Nanoparticle Interaction

Cited by 167 publications

References 42 publications

Multiphase microfluidic synthesis of micro- and nanostructures for pharmaceutical applications

Multiphase microfluidic synthesis of micro- and nanostructures for pharmaceutical applications

Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy

Composite core-shell microparticles from microfluidics for synergistic drug delivery

Contact Info

Product

Resources

About